Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023

BUY
$0.43 - $0.9 $11,232 - $23,509
26,122 Added 137.11%
45,174 $19,000
Q4 2022

Feb 14, 2023

SELL
$0.42 - $18.8 $3,254 - $145,681
-7,749 Reduced 28.91%
19,052 $12,000
Q3 2022

Nov 14, 2022

SELL
$0.58 - $18.2 $2,989 - $93,821
-5,155 Reduced 16.13%
26,801 $23,000
Q2 2022

Aug 15, 2022

BUY
$0.47 - $1.29 $5,698 - $15,639
12,124 Added 61.13%
31,956 $18,000
Q1 2022

May 16, 2022

SELL
$0.96 - $1.78 $7,754 - $14,378
-8,078 Reduced 28.94%
19,832 $22,000
Q4 2021

Feb 14, 2022

SELL
$1.56 - $2.99 $42,773 - $81,982
-27,419 Reduced 49.56%
27,910 $48,000
Q3 2021

Nov 15, 2021

SELL
$2.73 - $4.13 $67,835 - $102,622
-24,848 Reduced 30.99%
55,329 $170,000
Q2 2021

Aug 11, 2021

BUY
$2.18 - $4.29 $114,517 - $225,357
52,531 Added 190.01%
80,177 $313,000
Q1 2021

May 17, 2021

BUY
$2.69 - $5.12 $15,152 - $28,840
5,633 Added 25.59%
27,646 $77,000
Q4 2020

Feb 16, 2021

BUY
$2.25 - $7.12 $25,265 - $79,950
11,229 Added 104.13%
22,013 $67,000
Q3 2020

Nov 16, 2020

BUY
$3.46 - $8.39 $37,312 - $90,477
10,784 New
10,784 $66,000
Q1 2020

May 15, 2020

SELL
$2.46 - $5.84 $44,845 - $106,463
-18,230 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.8 - $13.43 $13,861 - $103,424
7,701 Added 73.14%
18,230 $50,000
Q3 2019

Nov 14, 2019

SELL
$8.12 - $14.54 $10,369 - $18,567
-1,277 Reduced 10.82%
10,529 $128,000
Q2 2019

Aug 16, 2019

BUY
$9.6 - $22.85 $113,337 - $269,767
11,806 New
11,806 $135,000

Others Institutions Holding CYCN

# of Institutions
1
Shares Held
293K
Call Options Held
0
Put Options Held
0

About Cyclerion Therapeutics, Inc.


  • Ticker CYCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,479,800
  • Market Cap $153M
  • Description
  • Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...
More about CYCN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.